可溶性 ACE2 作为 COVID-19 的一种潜在治疗方法。
Soluble ACE2 as a potential therapy for COVID-19.
机构信息
Wake Forest School of Medicine, Bowman Gray Center for Medical Education, Winston-Salem, North Carolina.
Division of Allergy and Immunology, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida.
出版信息
Am J Physiol Cell Physiol. 2021 Mar 1;320(3):C279-C281. doi: 10.1152/ajpcell.00478.2020. Epub 2021 Jan 27.
Abstract
Soluble angiotensin-converting enzyme 2 (sACE2) could be a therapeutic option to treat coronavirus disease 2019 (COVID-19) infection. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) utilizes ACE2 receptors on cell surfaces to gain intracellular entry, making them an ideal target for therapy. High-affinity variants of sACE2, engineered using high-throughput mutagenesis, are capable of neutralizing COVID-19 infection as decoy receptors. These variants compete with native ACE2 present on cells by binding with spike (S) protein of SARS-CoV-2, making native ACE2 on cell surfaces available to convert angiotensin II to angiotensin-1,7, thus alleviating the exaggerated inflammatory response associated with COVID-19 infection. This article explores the use of sACE2 as potential therapy for COVID-19 infection.
摘要
可溶性血管紧张素转换酶 2（sACE2）可能是治疗 2019 年冠状病毒病（COVID-19）感染的一种治疗选择。严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）利用细胞表面上的 ACE2 受体获得细胞内进入，使其成为治疗的理想目标。使用高通量诱变工程设计的高亲和力 sACE2 变体能够作为诱饵受体中和 COVID-19 感染。这些变体通过与 SARS-CoV-2 的刺突（S）蛋白结合与细胞表面上的天然 ACE2 竞争，使细胞表面上的天然 ACE2 能够将血管紧张素 II 转化为血管紧张素-1,7，从而减轻与 COVID-19 感染相关的过度炎症反应。本文探讨了使用 sACE2 作为 COVID-19 感染潜在治疗方法的可能性。
相似文献
1
Soluble ACE2 as a potential therapy for COVID-19.可溶性 ACE2 作为 COVID-19 的一种潜在治疗方法。
Am J Physiol Cell Physiol. 2021 Mar 1;320(3):C279-C281. doi: 10.1152/ajpcell.00478.2020. Epub 2021 Jan 27.
2
Killing Two Birds with One Stone by Administration of Soluble ACE2: A Promising Strategy to Treat Both Cardiovascular Diseases and SARS-CoV-2 Infection.可溶性 ACE2 给药“一石二鸟”：治疗心血管疾病和 SARS-CoV-2 感染的有前途策略。
Viruses. 2021 Nov 8;13(11):2243. doi: 10.3390/v13112243.
3
Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.血管紧张素转换酶 2（ACE2）在 COVID-19 所致急性呼吸窘迫综合征发病机制中的作用。
Front Immunol. 2021 Dec 22;12:732690. doi: 10.3389/fimmu.2021.732690. eCollection 2021.
4
Engineering ACE2 decoy receptors to combat viral escapability.工程 ACE2 诱饵受体以对抗病毒逃逸。
Trends Pharmacol Sci. 2022 Oct;43(10):838-851. doi: 10.1016/j.tips.2022.06.011. Epub 2022 Jul 25.
5
Engineered small extracellular vesicles displaying ACE2 variants on the surface protect against SARS-CoV-2 infection.经工程改造的小细胞外囊泡在表面展示 ACE2 变体，可预防 SARS-CoV-2 感染。
J Extracell Vesicles. 2022 Jan;11(1):e12179. doi: 10.1002/jev2.12179.
6
Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.SARS-CoV-2 变体 B.1.617.1 (Kappa)、B.1.617.2 (Delta) 和 B.1.618 的细胞进入和免疫逃逸特性。
mBio. 2022 Apr 26;13(2):e0009922. doi: 10.1128/mbio.00099-22. Epub 2022 Mar 10.
7
Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system.可溶性 ACE2 通过与肾素-血管紧张素系统相关蛋白的相互作用介导 SARS-CoV-2 的细胞进入。
Cell. 2021 Apr 15;184(8):2212-2228.e12. doi: 10.1016/j.cell.2021.02.053. Epub 2021 Mar 2.
8
Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).通过中断严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白与血管紧张素转换酶2（ACE2）之间的相互作用来实现SARS-CoV-2早期进入的潜在治疗方法。
Biochem Pharmacol. 2021 Oct;192:114724. doi: 10.1016/j.bcp.2021.114724. Epub 2021 Aug 8.
9
The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.hACE2 受体蛋白的表达及其在 SARS-CoV-2 进入、发病机制中的作用及其作为潜在治疗靶点的应用。
Tumour Biol. 2021;43(1):177-196. doi: 10.3233/TUB-200084.
10
Rational design of AAVrh10-vectored ACE2 functional domain to broadly block the cell entry of SARS-CoV-2 variants.AAVrh10 载体 ACE2 功能域的合理设计可广泛阻断 SARS-CoV-2 变体的细胞进入。
Antiviral Res. 2022 Sep;205:105383. doi: 10.1016/j.antiviral.2022.105383. Epub 2022 Jul 30.
引用本文的文献
1
Nucleic acid-based nanotherapeutics for treating sepsis and associated organ injuries.用于治疗脓毒症及相关器官损伤的核酸纳米疗法。
Theranostics. 2024 Jul 16;14(11):4411-4437. doi: 10.7150/thno.98487. eCollection 2024.
2
Seasonal human coronaviruses OC43, 229E, and NL63 induce cell surface modulation of entry receptors and display host cell-specific viral replication kinetics.季节性人类冠状病毒 OC43、229E 和 NL63 诱导细胞表面进入受体的调制，并显示宿主细胞特异性的病毒复制动力学。
Microbiol Spectr. 2024 Jul 2;12(7):e0422023. doi: 10.1128/spectrum.04220-23. Epub 2024 Jun 12.
3
COVID-19 and Gastrointestinal Tract: From Pathophysiology to Clinical Manifestations.新型冠状病毒肺炎与消化道：从病理生理学到临床表现。
Medicina (Kaunas). 2023 Sep 24;59(10):1709. doi: 10.3390/medicina59101709.
4
Molecular Analysis of Hot-Spot Regions of ACE2 and TMPRSS2 in SARS-CoV-2 "Invulnerable" Individuals.SARS-CoV-2“不易感染”个体中ACE2和TMPRSS2热点区域的分子分析
Cureus. 2023 Aug 11;15(8):e43344. doi: 10.7759/cureus.43344. eCollection 2023 Aug.
5
SARS-CoV-2 and the host-immune response.严重急性呼吸综合征冠状病毒 2 型与宿主免疫应答。
Front Immunol. 2023 Jun 19;14:1195871. doi: 10.3389/fimmu.2023.1195871. eCollection 2023.
6
Endotheliopathy in Acute COVID-19 and Long COVID.急性 COVID-19 和长新冠中的血管内皮病。
Int J Mol Sci. 2023 May 4;24(9):8237. doi: 10.3390/ijms24098237.
7
Thraustochytrid hosts for expression of proteins relevant to SARS-CoV-2 intervention.与 SARS-CoV-2 干预相关的蛋白质表达的厚壳蛤宿主。
PLoS One. 2023 Apr 12;18(4):e0283592. doi: 10.1371/journal.pone.0283592. eCollection 2023.
8
Identification of the regulatory mechanism of ACE2 in COVID-19-induced kidney damage with systems genetics approach.采用系统遗传学方法鉴定 ACE2 在 COVID-19 诱导的肾损伤中的调控机制。
J Mol Med (Berl). 2023 Apr;101(4):449-460. doi: 10.1007/s00109-023-02304-9. Epub 2023 Mar 23.
9
Role of Vitamin D, ACE2 and the Proteases as TMPRSS2 and Furin on SARS-CoV-2 Pathogenesis and COVID-19 Severity.维生素 D、ACE2 和蛋白酶（如 TMPRSS2 和 Furin）在 SARS-CoV-2 发病机制和 COVID-19 严重程度中的作用。
Arch Med Res. 2023 Apr;54(3):223-230. doi: 10.1016/j.arcmed.2023.02.002. Epub 2023 Feb 14.
10
S Protein, ACE2 and Host Cell Proteases in SARS-CoV-2 Cell Entry and Infectivity; Is Soluble ACE2 a Two Blade Sword? A Narrative Review.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）进入细胞及感染性过程中的刺突蛋白（S蛋白）、血管紧张素转换酶2（ACE2）和宿主细胞蛋白酶；可溶性ACE2是双刃剑吗？一篇综述
Vaccines (Basel). 2023 Jan 17;11(2):204. doi: 10.3390/vaccines11020204.
本文引用的文献
1
Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With the Risk of Hospitalization and Death in Hypertensive Patients With COVID-19.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂与 COVID-19 合并高血压患者住院和死亡风险的关系。
J Am Heart Assoc. 2021 Jul 6;10(13):e018086. doi: 10.1161/JAHA.120.018086. Epub 2021 Feb 24.
2
Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor: Therapeutic Implications.SARS-CoV-2 与其他冠状病毒与 ACE（血管紧张素转换酶）-2 作为其主要受体的相互作用：治疗意义。
Hypertension. 2020 Nov;76(5):1339-1349. doi: 10.1161/HYPERTENSIONAHA.120.15256. Epub 2020 Aug 27.
3
Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2.工程改造人血管紧张素转换酶 2 以优化其与严重急性呼吸综合征冠状病毒 2 刺突蛋白的结合。
Science. 2020 Sep 4;369(6508):1261-1265. doi: 10.1126/science.abc0870. Epub 2020 Aug 4.
4
Renin-Angiotensin System Blockade in COVID-19: Good, Bad, or Indifferent?新型冠状病毒肺炎中肾素 - 血管紧张素系统阻断：有益、有害还是无关紧要？
J Am Coll Cardiol. 2020 Jul 21;76(3):277-279. doi: 10.1016/j.jacc.2020.06.003.
5
Pathological Role of Angiotensin II in Severe COVID-19.血管紧张素II在重症新型冠状病毒肺炎中的病理作用
TH Open. 2020 Jun 26;4(2):e138-e144. doi: 10.1055/s-0040-1713678. eCollection 2020 Apr.
6
Angiotensin converting enzyme-2 as therapeutic target in COVID-19.血管紧张素转换酶2作为COVID-19的治疗靶点
Diabetes Metab Syndr. 2020 Jul-Aug;14(4):637-639. doi: 10.1016/j.dsx.2020.05.022. Epub 2020 May 12.
7
Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2.使用临床级别的可溶性人血管紧张素转化酶 2 抑制工程化人类组织中的 SARS-CoV-2 感染。
Cell. 2020 May 14;181(4):905-913.e7. doi: 10.1016/j.cell.2020.04.004. Epub 2020 Apr 24.
8
COVID-19, ACE2, and the cardiovascular consequences.新型冠状病毒肺炎、血管紧张素转化酶 2 与心血管系统并发症
Am J Physiol Heart Circ Physiol. 2020 May 1;318(5):H1084-H1090. doi: 10.1152/ajpheart.00217.2020. Epub 2020 Mar 31.
9
Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?可溶性血管紧张素转化酶 2：冠状病毒感染治疗的潜在方法？
Clin Sci (Lond). 2020 Mar 13;134(5):543-545. doi: 10.1042/CS20200163.
10
Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.血管紧张素受体阻滞剂可作为治疗 SARS-CoV-2 的候选药物。
Drug Dev Res. 2020 Aug;81(5):537-540. doi: 10.1002/ddr.21656. Epub 2020 Mar 4.
Zotero 插件